Eurofins Scientific SE
DUS:ESF0
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.76
72.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eurofins Scientific SE
In the intricate realm of scientific services, Eurofins Scientific SE emerges as a quintessential powerhouse, orchestrating a symphony of analysis and testing across various industries. Founded in 1987, Eurofins began its journey with a focus on groundbreaking scientific methods for food and agriculture sectors. However, it rapidly diversified its expertise, leveraging its analytical prowess to expand into pharmaceuticals, environmental testing, and clinical diagnostics. The company operates through a network of laboratories scattered across the globe, each one serving as a beacon of quality and precision, embodying Eurofins' commitment to safeguarding consumer health, ensuring product safety, and supporting regulatory compliance. This robust infrastructure allows Eurofins to produce a constant stream of detailed and reliable test results, fueling its reputation and securing its place in the global market.
Eurofins generates revenue primarily through its comprehensive suite of testing services, which cut across multiple sectors. Clients range from large corporations and government bodies to individual consumers who require specific tests. The company capitalizes on its broad spectrum of specialized tests, from determining the complex composition of food products to detecting elusive contaminants in pharmaceuticals and performing critical genetic screenings. This creates a diversified revenue stream that minimizes dependency on any single industry or service line. Eurofins' ability to continuously innovate and adapt its offerings ensures an ongoing inflow of clients seeking unparalleled testing accuracy and expertise. The combination of this vast service portfolio and relentless pursuit of scientific advancement underpins Eurofins' impressive financial performance and solidifies its pivotal role in the scientific services industry.
In the intricate realm of scientific services, Eurofins Scientific SE emerges as a quintessential powerhouse, orchestrating a symphony of analysis and testing across various industries. Founded in 1987, Eurofins began its journey with a focus on groundbreaking scientific methods for food and agriculture sectors. However, it rapidly diversified its expertise, leveraging its analytical prowess to expand into pharmaceuticals, environmental testing, and clinical diagnostics. The company operates through a network of laboratories scattered across the globe, each one serving as a beacon of quality and precision, embodying Eurofins' commitment to safeguarding consumer health, ensuring product safety, and supporting regulatory compliance. This robust infrastructure allows Eurofins to produce a constant stream of detailed and reliable test results, fueling its reputation and securing its place in the global market.
Eurofins generates revenue primarily through its comprehensive suite of testing services, which cut across multiple sectors. Clients range from large corporations and government bodies to individual consumers who require specific tests. The company capitalizes on its broad spectrum of specialized tests, from determining the complex composition of food products to detecting elusive contaminants in pharmaceuticals and performing critical genetic screenings. This creates a diversified revenue stream that minimizes dependency on any single industry or service line. Eurofins' ability to continuously innovate and adapt its offerings ensures an ongoing inflow of clients seeking unparalleled testing accuracy and expertise. The combination of this vast service portfolio and relentless pursuit of scientific advancement underpins Eurofins' impressive financial performance and solidifies its pivotal role in the scientific services industry.
Organic Growth: Eurofins reported 7.5% organic growth in the nine months, which is 100 basis points above its objective, despite headwinds in several markets.
COVID Revenue Impact Fading: The drag from lost COVID-related revenues is now largely behind the business, making future quarters more comparable year-over-year.
Biopharma Resilience: Biopharma remains strong with most activity in later-stage product testing for big pharma, while the Discovery segment stays soft.
Margin Outlook: Margins are expected to meet annual objectives, with inflation better compensated in 2023 and further improvements expected as integrations and lab consolidations are completed.
Guidance Reiterated: Management reiterated its full-year objectives for growth and margin, expressing confidence despite macroeconomic uncertainty, especially in Europe.
Startups & CapEx: About EUR 100 million will be invested in start-ups and restructuring this year, supporting organic growth and network expansion.
M&A Approach: Eurofins remains disciplined on acquisitions, waiting for more attractive prices, and continues to target EUR 250 million of acquired revenue per year on average over five years.
